ClinicalTrials.gg
Not yet recruitingNCT06821763Updated Feb 12, 2025

To Measure Post Operative Pain Severity by Using Two Different Intra Canal Medicaments Calcium Hydroxide and Triple Antibiotic Paste in Teeth with Single Roots and Periapical Disease Called Apical Periodontitis

A Phase 2/3 interventional study of Calcium Hydroxide Intracanal medication and triple antibiotic paste (TAP) in Apical Periodontitis and Irreversible Pulpitis with Apical Periodontitis, sponsored by Komal Ashraf Khan. Not yet recruiting at 1 site in Pakistan. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Komal Ashraf Khan · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
12 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Periapical Periodontitis with a site in Pakistan — 4 open to participants now, 5 under way, 1 of them phase 3. Periapical Periodontitis · Pakistan.

Planned enrollment
3rd of 14
180 · median 85
Started
2025
with 3 others
Phase 2/3
2 of 14
1 open now
Registered
7th of 14
by date
Lead sponsor
1 of 14
Komal Ashraf Khan

Among the 14 studies in Periapical Periodontitis with a site in Pakistan, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2025, is one of 2 in phase 2/3, and was the 7th registered.

Periapical Periodontitis

281 studies on the registry are indexed under Periapical Periodontitis; 79 are open to participants now.

Browse Periapical Periodontitis studies →

Open to participants now

4 of the 14 studies in Periapical Periodontitis with a site in Pakistan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 43 Periapical Periodontitis studies recruiting now, 17 (40%) set no upper age limit and 25 (58%) stop at 75 or younger; 5 take children under 18; 21 take healthy volunteers.

This study: 12 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Periapical Periodontitis with a site in Pakistan, or all of them as a file.
02

Study summary

  • The aim of this study is to compare post operative pain effectiveness between two most commonly available intra canal medicaments that are Triple Antibiotic Paste and Calcium Hydroxide during root canal treatment of single rooted teeth with symptomatic apical periodontitis.
  • Patients visiting OPD will be selected after fulfilment of inclusion criteria and randomly divided into two groups i.e group A patients receiving calcium hydroxide and group B with patients receiving Triple Antibiotic Paste as intra canal medicaments
  • Patient will be called at 48hrs 72hrs and 96hrs postoperatively.
  • Effectiveness of intra canal medicaments will be measured as no mild moderate severe on visual analogue scale(VAS).
Read the detailed description
  • This randomized control study is done to compare post operative pain effectiveness of two medicaments that are triple antibiotic paste (TAP)(ciprofloxacin, metronidazole and minocycline in ratio 1:1:1) and calcium hydroxide(CH) during root canal treatment of single rooted teeth with symptomatic apical periodontitis.
  • Calcium hydroxide being strong base exerts antimicrobial efficiency in reducing and eliminating microorganisms in entire root canal system
  • TAP is efficient against calcium hydroxide resistant bacteria called as enterococcus faecalis and provides antimicrobial efficiency to inner depths of root canal up to 400 microns.
  • This study will add further to literature regarding better intracanal medicament among two most widely used.
  • Sample size includes total 180 participants having two groups each containing 90.
  • Inclusion criteria have patients with age group 12-45, single rooted teeth, having symptomatic apical periodontitis, patients fulfilling international associates definition of pain
  • Exclusion criteria includes patients having allergies, unable to take medications, medical conditions like diabetes etc, pregnant patients, teeth with tooth abnormalities like dilacerations open apices etc
  • Patients will be selected from OPD after fulfilment of inclusion criteria randomly divided into two groups using lottery method
  • Group A receiving calcium hydroxide group B receiving triple antibiotic paste
  • Patients will be called post operatively after 48hrs 72hrs and 96hrs
  • Post operative pain effectiveness will be measured as no mild moderate and severe on visual analogue scale (VAS)
  • The data will be analyzed in statistical software SPSS v 25. Chi square test will be applied to compare effectiveness in both groups keeping p value less than 0.05 as significant.
03

Conditions studied

  • Apical Periodontitis
  • Irreversible Pulpitis with Apical Periodontitis
04

Who can participate

Ages eligible
12 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both genders having age 12-45 years
  • Newly diagnosed cases fulfilling the criteria of INTERNATIONAL ASSOCIATES FOR THE STUDY OF PAIN definition of pain.
  • A Single rooted teeth (Anterior or Posterior)
  • Teeth with symptomatic apical periodontitis
  • Teeth with necrotic pulp that gave a negative response to vitality testing.

Exclusion criteria

Exclusion Criteria:

  • Patients who have allergies, sensitivity or unable to take medications, periodontal disease, acute endodontic or periodontal abscess, requiring prophylactic antibiotics, systemic diseases like hypertension, diabetes, liver dysfunction renal failure and mental disabilities were excluded.
  • Pregnant ladies or patients on nursing were also excluded from the sample.
  • Teeth with anatomical difficulties such as open apices.
  • Teeth with severe dilacerations, calcified canals, occlusal interferences, chronic periodontitis, internal/external root resorption.
  • Patients with serious medical illness, systemic disorders, diseases such as AIDS or .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    Group A( calcium hydroxide)

    patients receiving calcium hydroxide as intra canal medicament

    Drug: Calcium Hydroxide Intracanal medication

  • Active comparator
    Group B( Triple Antibiotic Paste)

    Patients receiving triple antibiotic paste as intra canal medicament

    Drug: triple antibiotic paste (TAP)

Interventions

  • DrugCalcium HydroxideStudies of Calcium HydroxideCalcium Hydroxide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    non setting calcium hydroxide(CH) mixed with normal saline and placed as intra canal medicament during first visit of root canal treatment. effectiveness measured after 48hrs, 72hrs and 96hrs

  • Drugtriple antibiotic paste (TAP)

    mix metronidazole, ciprofloxacin and minocycline in ratio 1:1:1 with normal saline and placed as intra canal medicament during first visit of root canal treatment.

06

What researchers measure

Primary outcomes

  1. post operative pain

    post operative pain measured through visual analogue scale( VAS) from readings no pain 0, mild taken as 0-2, moderate as 2-5, severe taken as 5-10

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Oct 2025, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Feb 12, 2025
StartEst.
May 1, 2025
Primary completionEst.
Oct 1, 2025
CompletionEst.
Nov 1, 2025
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06821763
Lead sponsor
Komal Ashraf Khan
Responsible party
Komal Ashraf Khan (Post Graduate Trainee, Margalla Institute of Health Sciences) — Sponsor-investigator
First posted
Feb 12, 2025
Start date
May 1, 2025 (estimated)
Primary completion
Oct 1, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Feb 12, 2025

Study contacts

Komal Ashraf Khan
Contact
komalashraf152@gmail.com
+92 3129433556
Dr. Lubna Pasha
Contact
+92 333 9499959

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Calcium Hydroxide

Start the discussion